Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – Q4 2015
GlobalData’s “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – Q4 2015” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions….
Total Pages: 148
GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q4 2015” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q4 2015. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.
Data presented in this report is derived from GlobalData’s proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research
Scope
- Analysis of the market trends for the pharmaceutical industry in the global arena.
- Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
- Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
- Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
- Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
- Analysis of partnership and licensing deals based on clinical stage of development of products.
- Summary of the pharmaceutical deals globally in the five quarters.
- Information on the top deals happened in the pharmaceutical industry.
- Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
- League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs
Reasons to buy
- Enhance your decision making capability in a more rapid and time sensitive manner.
- Find out the major deal performing segments for investments in your industry.
- Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
- Identify companies that are aggressively looking to raise capital in the market
- Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
- Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
- Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
- Identify growth segments and opportunities in each region within the industry.
- Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.
Table of Contents
1 Table of Contents 2
1.1 List of Tables 7
1.2 List of Figures 12
2 Pharmaceuticals & Healthcare, Global, Deal Summary, Q4 2015 16
2.1 Pharmaceuticals & Healthcare, Global, Deals Analysis, Q4 2015 16
2.2 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, Q4 2015 19
2.3 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, Q4 2015 20
2.4 Pharmaceuticals & Healthcare, Global, Top Deals, Q4 2015 21
2.4.1 Allergan and Pfizer to Combine in USD160 Billion Deal 21
2.4.2 Shire Acquires Dyax 22
2.4.3 AstraZeneca Prices Public Offering of Notes for USD6 Billion 23
2.4.4 Sanofi to Enter into Licensing Agreement with Hanmi Pharma 23
2.4.5 AstraZeneca Acquires 55% Stake in Acerta Pharma 24
3 Pharmaceuticals & Healthcare, Global, Deals Summary, by Type 25
3.1 Pharmaceuticals & Healthcare, Global, M&A, Q4 2015 25
3.1.1 Top M&A Deals in Q4 2015 26
3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals, by Therapy Area, Q4 2014 - Q4 2015 27
3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Q4 2015 29
3.2.1 Top Initial Public Offerings in Q4 2015 30
3.2.2 Top Secondary Offerings in Q4 2015 31
3.2.3 Top PIPE Deals in Q4 2015 31
3.2.4 Pharmaceuticals & Healthcare, Global, Top IPOs Share Performance, Q4 2014-Q4 2015 31
3.2.5 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Q4 2014 - Q4 2015 32
3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, Q4 2015 34
3.3.1 Top Venture Financing Deals in Q4 2015 35
3.3.2 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q4 2015 36
3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q4 2015 37
3.3.4 Pharmaceuticals & Healthcare, Global, Venture Capital, by Therapy Area, Q4 2014 - Q4 2015 38
3.3.5 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Q4 2014 - Q4 2015 40
3.3.6 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q4 2014 - Q4 2015 42
3.4 Pharmaceuticals & Healthcare, Global, Private Equity Deals, Q4 2015 43
3.4.1 Top Private Equity Deals in Q4 2015 44
3.4.2 Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Q4 2014 - Q4 2015 45
4 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q4 2015 47
4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q4 2015 47
4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Q4 2014 - Q4 2015 49
4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q4 2015 51
4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Deal Values, Q4 2015 52
4.3.2 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q4 2015 53
4.3.3 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payments, Q4 2015 53
4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), Q4 2014 - Q4 2015 54
4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals, Q4 2014 - Q4 2015 56
4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Deal Values (US$ m), Q4 2014 - Q4 2015 57
4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q4 2014 - Q4 2015 59
5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, Q4 2015 61
5.1 Pharmaceutical & Healthcare, Global, Licensing Agreements, Q4 2015 61
5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q4 2014 - Q4 2015 63
5.2.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Deal Value, Q4 2015 64
5.2.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, Q4 2015 65
5.2.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Milestone Payment, Q4 2015 65
5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Total Deal Value (US$ m), Q4 2014 - Q4 2015 66
5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront Payments Vs Milestone Payments (US$ m), Q4 2014 - Q4 2015 68
5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q4 2014 - Q4 2015 70
5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q4 2014 - Q4 2015 71
5.7 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Upfront Payments Vs Milestone Payments (US$ m), Q4 2014 - Q4 2015 73
6 Pharmaceuticals & Healthcare, Global, M&A Financial Analysis 75
6.1 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value versus Median Deal Value, Q4 2014 - Q4 2015 75
6.2 Pharmaceuticals& Healthcare, Global Acquisitions, Average Price Earnings of Acquired Companies, Q4 2014 - Q4 2015 77
6.3 Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q4 2014 - Q4 2015 78
6.4 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value per Operating Profit, Q4 2014 - Q4 2015 80
6.5 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share versus Average Market Price Per Share, Q4 2014 - Q4 2015 82
6.6 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q4 2014 - Q4 2015 84
7 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 86
7.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, Q4 2015 86
7.1.1 Oncology - Deals of the Quarter 88
7.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, Q4 2015 91
7.2.1 Central Nervous System - Deals of the Quarter 93
7.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, Q4 2015 95
7.3.1 Infectious Disease - Deals of the Quarter 97
7.4 Pharmaceuticals & Healthcare, Global, Immunology Deals, Q4 2015 99
7.4.1 Immunology - Deals of the Quarter 101
7.5 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, Q4 2015 104
7.5.1 Metabolic Disorders - Deals of the Quarter 106
7.6 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, Q4 2015 108
7.6.1 Cardiovascular - Deals of the Quarter 110
7.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, Q4 2015 112
7.7.1 Gastrointestinal - Deals of the Quarter 114
7.8 Pharmaceuticals & Healthcare, Global, Hematological Disorders Deals, Q4 2015 116
7.8.1 Hematological Disorders - Deals of the Quarter 117
7.9 Pharmaceuticals & Healthcare, Global, Respiratory Deals, Q4 2015 119
7.9.1 Respiratory - Deals of the Quarter 120
7.10 Pharmaceuticals & Healthcare, Global, Dermatology Deals, Q4 2015 122
7.10.1 Dermatology - Deals of the Quarter 124
8 Deal Summary by Geography 125
8.1 Pharmaceuticals & Healthcare, North America Region, Deals, Q4 2015 125
8.1.1 North America - Deals of the Quarter 127
8.2 Pharmaceuticals & Healthcare, Europe Region, Deals, Q4 2015 129
8.2.1 Europe - Deals of the Quarter 131
8.3 Pharmaceuticals & Healthcare, Asia-Pacific, Deals, Q4 2015 133
8.3.1 Asia-Pacific - Deals of the Quarter 135
8.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, Q4 2015 136
8.4.1 Rest of the World - Deals of the Quarter 138
9 Pharmaceuticals & Healthcare, Global, Top Advisors 139
9.1 Pharmaceuticals & Healthcare, Global Top Financial Advisors, M&A, Q4 2014 - Q4 2015 139
9.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Q4 2014 - Q4 2015 141
10 Appendix 143
11 Further Information 145
11.1 Methodology 145
11.2 About GlobalData 146
11.3 Disclosure information 146
11.4 Disclaimer 147
1.1 List of Tables
Table 1: Pharmaceuticals & Healthcare, Global, Deal Summary, Number of Deals and Deal Values (US$m), Q4 2014 - Q4 2015 18
Table 2: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), Q4 2015 20
Table 3: Pharmaceuticals & Healthcare, Global, Top Deals, Q4 2015 21
Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 26
Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, Q4 2015 26
Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, , Q4 2014 - Q4 2015 28
Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$m), Q4 2014 - Q4 2015 30
Table 8: Pharmaceuticals & Healthcare, Global, Top Initial Public Offering Deals, Q4 2015 30
Table 9: Pharmaceuticals & Healthcare, Global, Top Secondary Offering Deals, Q4 2015 31
Table 10: Pharmaceuticals & Healthcare, Global, Top PIPE Deals, Q4 2015 31
Table 11: Pharmaceuticals & Healthcare, Global, Top IPOs Share Performance, Q4 2014-Q4 2015 31
Table 12: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$m), Q4 2014 - Q4 2015 33
Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 35
Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Capital Deals, Q4 2015 35
Table 15: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals and Deal Values (%), Q4 2015 37
Table 16: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q4 2014 - Q4 2015 39
Table 17: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 41
Table 18: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q4 2014 - Q4 2015 42
Table 19: Pharmaceuticals & Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 44
Table 20: Pharmaceuticals & Healthcare, Global, Top Private Equity Deals, Q4 2015 44
Table 21: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q4 2014 - Q4 2015 46
Table 22: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 48
Table 23: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 50
Table 24: Pharmaceuticals & Healthcare, Partnership Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q4 2014 - Q4 2015 52
Table 25: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront & Milestone Payments and Deal Values (US$ m), Q4 2015 52
Table 26: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q4 2015 53
Table 27: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payment, Q4 2015 53
Table 28: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q4 2014 - Q4 2015 55
Table 29: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q4 2014 - Q4 2015 58
Table 30: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payment and Deal Values (US$ m), Q4 2014 - Q4 2015 60
Table 31: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deal Summary, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 62
Table 32: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront & Milestone Payments and Deal Values (US$ m), Q4 2014 - Q4 2015 64
Table 33: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Deal Values, Q4 2015 64
Table 34: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Upfront Payment, Q4 2015 65
Table 35: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Milestone Payment, Q4 2015 65
Table 36: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 67
Table 37: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment (US$ m), Q4 2014 - Q4 2015 69
Table 38: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q4 2014 - Q4 2015 72
Table 39: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment and Deal Values (US$ m), Q4 2014 - Q4 2015 74
Table 40: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value vs Median Deal Value, (US$m), Q4 2014 - Q4 2015 76
Table 41: Pharmaceuticals & Healthcare, Global Acquisitions, Average P/E of Acquired Companies, Q4 2014 - Q4 2015 77
Table 42: Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q4 2014 - Q4 2015 79
Table 43: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Operating Profit, Q4 2014 - Q4 2015 81
Table 44: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Market Price Per Share, Q4 2014 - Q4 2015 83
Table 45: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q4 2014 - Q4 2015 85
Table 46: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 87
Table 47: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 92
Table 48: Pharmaceuticals & Healthcare, Global, Infectious Disease, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 96
Table 49: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 100
Table 50: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 105
Table 51: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 109
Table 52: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 113
Table 53: Pharmaceuticals & Healthcare, Global, Hematological Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 117
Table 54: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 120
Table 55: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 123
Table 56: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 126
Table 57: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 130
Table 58: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 134
Table 59: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 137
Table 60: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 140
Table 61: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 142
Table 62: Pharmaceuticals & Healthcare, Deals’ Key Financials, Global Acquisition Deals, Q4 2014-Q4 2015 143
1.2 List of Figures
Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$m), Q4 2014 - Q4 2015 16
Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), Q4 2015 19
Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), Q4 2015 20
Figure 4: Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (US$m), Q4 2014 - Q4 2015 25
Figure 5: Pharmaceuticals & Healthcare, Global, M&As, by Therapy Area, Number of Deals and Deal Values (US$m), by Therapy Area, Q4 2014 - Q4 2015 27
Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 29
Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$m), , Q4 2014 - Q4 2015 32
Figure 8: Pharmaceuticals & Healthcare, Global, Venture Capital, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 34
Figure 9: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals (%), Q4 2015 36
Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Deal Values (%), Q4 2015 37
Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q4 2014 - Q4 2015 38
Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 40
Figure 13: Pharmaceuticals & Healthcare, Global, Private Equity, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 43
Figure 14: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q4 2014 - Q4 2015 45
Figure 15: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 47
Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 49
Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront & Milestone Payment and Deal Values (US$ m), Q4 2014 - Q4 2015 51
Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q4 2014 - Q4 2015 54
Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q4 2014 - Q4 2015 56
Figure 20: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q4 2014 - Q4 2015 57
Figure 21: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payment and Deal Values (US$ m), Q4 2014 - Q4 2015 59
Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 61
Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q4 2014 - Q4 2015 63
Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 66
Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront & Milestone Payments and Deal Values (US$ m), Q4 2014 - Q4 2015 68
Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Number Of Deals, Q4 2014 - Q4 2015 70
Figure 27: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Deal Values (US$ m), Q4 2014 - Q4 2015 71
Figure 28: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q4 2014 - Q4 2015 73
Figure 29: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value vs Median Deal Value, (US$m), Q4 2014 - Q4 2015 75
Figure 30: Pharmaceuticals & Healthcare, Global Acquisitions, Average P/E of Acquired Companies, Q4 2014 - Q4 2015 77
Figure 31: Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q4 2014 - Q4 2015 78
Figure 32: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value per Operating Profit, Q4 2014 - Q4 2015 80
Figure 33: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Market Price Per Share, Q4 2014 - Q4 2015 82
Figure 34: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q4 2014 - Q4 2015 84
Figure 35: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 86
Figure 36: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 91
Figure 37: Pharmaceuticals & Healthcare, Global, Infectious Disease, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 95
Figure 38: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 99
Figure 39: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 104
Figure 40: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 108
Figure 41: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 112
Figure 42: Pharmaceuticals & Healthcare, Global, Hematological Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 116
Figure 43: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 119
Figure 44: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 122
Figure 45: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 125
Figure 46: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 129
Figure 47: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 133
Figure 48: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 136
Figure 49: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 139
Figure 50: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 141
